K Number
K983971
Device Name
CARDIAC MARKER CONTROL MODULE, MODEL CCCM
Date Cleared
1998-11-18

(9 days)

Product Code
Regulation Number
862.1660
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdparty
Intended Use
The Cardiac Marker Control Module is an assayed, bi-level control module containing analytes (CK-MB, myoglobin, and troponin I) associated with acute myocardial infarction (AMI). It is intended as an aid in monitoring day-to-day assay performance.
Device Description
DPC's Cardiac Marker Control Module is an assayed, bi-level control intended for use with the IMMULITE CK-MB, IMMULITE Myoglobin, and IMMULITE Troponin I assays.
More Information

Not Found

Not Found

No
The document describes a quality control material for laboratory assays and contains no mention of AI or ML technology.

No
The device is described as a "control module" intended for "monitoring day-to-day assay performance" for analytes associated with acute myocardial infarction. It is explicitly stated as an "aid in monitoring," which indicates it is used for quality control of diagnostic tests, not for direct therapy or treatment of a disease.

No
Explanation: The device is a control module for monitoring day-to-day assay performance, not for diagnosing patients.

No

The device description clearly states it is a "control module" containing "analytes" and is intended for use with specific "assays," indicating it is a physical, chemical control material, not software.

Yes, this device is an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use explicitly states it's "intended as an aid in monitoring day-to-day assay performance." This means it's used in vitro (outside the body) to evaluate the performance of diagnostic tests.
  • Device Description: It's described as an "assayed, bi-level control intended for use with the IMMULITE CK-MB, IMMULITE Myoglobin, and IMMULITE Troponin I assays." These are all diagnostic assays used to measure substances in biological samples. The control module is used to ensure the accuracy and reliability of these diagnostic tests.

IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This control module fits that description by being used to monitor the performance of assays that analyze human specimens.

N/A

Intended Use / Indications for Use

The Cardiac Marker Control Module is an assayed, bi-level control module containing analytes (CK-MB, myoglobin, and troponin I) associated with acute myocardial infarction (AMI). It is intended as an aid in monitoring day-to-day assay performance.

Product codes

JJY, JJX

Device Description

DPC's Cardiac Marker Control Module is an assayed, bi-level control intended for use with the IMMULITE CK-MB, IMMULITE Myoglobin, and IMMULITE Troponin I assays.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies

Not applicable

Key Metrics

Not Found

Predicate Device(s)

Not Found

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 862.1660 Quality control material (assayed and unassayed).

(a)
Identification. A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.(b)
Classification. Class I (general controls). Except when intended for use in donor screening tests, quality control materials (assayed and unassayed) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.

0

K983971

510(k) Summary Safety and Effectiveness

This summary of safety and effectiveness information has been prepared in accordance with the requirements of SMDA 1990 and 21 CFR Part 807.92

| Name:
Address: | Diagnostic Products Corporation
5700 West 96th Street
Los Angeles, CA 90045-5597 |
|----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Telephone Number:
Facsimile Number: | (310) 645-8200
(310) 645-9999 |
| Contact Person: | Edward M. Levine, Ph.D.
Director of Clinical Affairs |
| Date of Preparation: | November 6, 1998 |
| Device Name:
Trade: | Cardiac Marker Control Module
Device intended as an aid in monitoring the performance of DPC's
IMMULITE® CK-MB, IMMULITE®Myoglobin, and IMMULITE®
Troponin I assays |
| Catalog Number: | CCCM |
| Classification: | Class I device, 75-JJY (21 CFR 862.1660) |
| Manufacturer: | Diagnostic Products Corporation
5700 West 96th Street
Los Angeles, CA 90045-5597 |
| Establishment
Registration #: | DPC's Establishment Registration No. is 2017183 |
| Description of Device: | DPC's Cardiac Marker Control Module is an assayed, bi-level
control intended for use with the IMMULITE CK-MB,
IMMULITE Myoglobin, and IMMULITE Troponin I assays. |
| Intended Use of the
Device: | The Cardiac Marker Control Module is an assayed, bi-level control
module containing analytes (CK-MB, myoglobin, and troponin I)
associated with acute myocardial infarction (AMI). It is intended
as an aid in monitoring day-to-day assay performance. |
| Clinical Studies: | Not applicable |

1

Conclusion:

The data presented in this summary of safety and effectiveness is the data that the Food and Drug
Administration used in granting DPC substantial equivalence for Module.

Edward A. Reiner

Edward M. Levine, Ph.D. Director of Clinical Affairs

11/6/98

Date

2

Image /page/2/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes coiled around it, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged in a circular pattern around the symbol. The caduceus is a common symbol associated with healthcare and medicine.

NOV 1 8 1998

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Edward M. Levine, Ph.D. Director of Clinical Affairs Diaqnostic Products Corporation 5700 West 96th Street Los Angeles, California 90045-5597

Re: K983971 Cardiac Marker Control Module Trade Name: Requlatory Class: I Product Code: JJX Dated: November 6, 1998 November 9, 1998 Received:

Dear Dr. Levine:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP requlation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations.

3

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Autman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

4

1498397 510(k) Number (if known): __ Device Name: Cardiac Marker Control Module

Indications For Use:

The Cardiac Marker Control Module is an assayed, bi-level control module containing analytes (CK-MB, myoglobin, and troponin I) associated with acute myocardial infarction (AMI). It is intended as an aid in monitoring day-to-day assay performance.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use
(Per 21 CFR 801 . 109)

OR

Over-The-Counter Use

(Optional Format 1-2-

9(6)

(Division Sign-Off)
Division of Clinical Laboratory Devices

10(k) Number: K983971